Physician-Initiated Access Request: how it works and where it is recognized

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

What Physician-Initiated Access is

Origin and authorising body. Multi-jurisdictional design pattern reflecting the architectural fact that named-patient and compassionate-use authorisations require a treating physician's request as the initiating event. The authorising body for each individual case is the destination-country regulator (varies) under the relevant named-patient or compassionate-use framework, acting under that jurisdiction's pharmacy or medicines legislation.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Legal basis. Physician-initiated access is not a separate statutory framework; it is the design pattern under which named-patient and compassionate-use authorisations originate. Every major framework requires a treating physician's clinical justification as the initiating document. The 'physician-initiated' label is sometimes used by manufacturers to distinguish their access programmes from patient-initiated direct-import schemes (such as India's Rule 36 or Japan's Yakkan Shomei).

Physician-Initiated Access Request describes the workflow under which the treating physician originates the access pathway by drafting a clinical justification letter, identifying the requested medicine, and submitting (or causing the submission of) the regulatory application to the destination-country authority. The framework is the operational architecture behind most named-patient, compassionate-use, and expanded-access programmes globally.

The physician-initiated nature of these requests creates a structural feature of cross-border access: the destination-country physician (not a patient, not a coordinator, not a manufacturer's commercial team) holds the prescription authority and the clinical responsibility. Reserve Meds and other coordinators operate around this fact: we prepare the clinical justification template, assemble the supporting documentation, coordinate the supply chain, but we do not replace the prescribing physician.

This page consolidates Reserve Meds's operational view of the Physician-Initiated Access Request framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Physician-Initiated Access Request-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.

Reserved for you.

Who can use Physician-Initiated Access

Physician-Initiated Access is used by any prescribing clinician operating under a named-patient, compassionate-use, or expanded-access framework. The physician must be licensed in the destination country and must accept clinical responsibility for the prescription.

In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.

Drug categories typically covered under Physician-Initiated Access

All categories accessible through named-patient, compassionate-use, and expanded-access frameworks: oncology, rare disease, dermatology, paediatrics, post-approval indications, advanced therapy medicinal products.

The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Physician-Initiated Access Request import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.

Country compatibility

The table below summarises how the Physician-Initiated Access Request framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Physician-Initiated Access Request dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Physician-Initiated Access Request clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.

Notes. "Indirect" means the destination regulator does not directly accept Physician-Initiated Access Request authorisation as the legal basis for import but does recognise a Physician-Initiated Access Request authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).

Documentation required

A Physician-Initiated Access application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).

• Physician's clinical justification letter.
• Physician licence verification.
• Patient identifier and clinical history.
• Informed consent.
• Destination-country regulator application form.
• Supporting documents per the relevant pathway.

Typical timeline

Timelines run on the underlying pathway (named-patient, compassionate-use, expanded-access). Routine cases: 5 to 25 business days for regulator review; end-to-end 4 to 8 weeks including logistics.

Costs and reimbursement

Costs run on the underlying pathway. Drug cost, logistics, customs, dispensing, and coordinator fees apply.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Physician-Initiated Access Request cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.

For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.

Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.

Next step

If your treating physician has identified a clinical need that fits the Physician-Initiated Access Request framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your caseWhatsApp

Reserved for you.

---

Related

• All access pathways
• UAE access landscape
• Saudi Arabia: SFDA named-patient pathway
• When conventional access fails
• How Reserve Meds works